Panel discussion – Health Economics
Precision medicine enables the delivery of the most appropriate treatment at the right time, based on individual factors such as a patient’s genetic profile, environment, and lifestyle. New advanced therapies are, in some cases, making it possible to cure conditions that were previously untreatable.
However, these treatments may involve high upfront costs. Small patient populations in clinical trials, together with uncertainty around long-term effectiveness, make cost–benefit assessments more complex than for traditional pharmaceuticals.
Panelists:
Peter Lindgren, Managing Director at IHE - The Swedish Institute for Health Economics, Professor of Health Economics at Karolinska Institutet, Fredrik Andersson, Chief Economist at Lif – The Swedish Association of the Pharmaceutical Industry, Anna Alaassad, Chief Strategist at TLV - The Dental and Pharmaceutical Benefits Agency.
Moderators: Andreas Namslauer, Process Manager & Filippa Kull, COO, Stockholm Science City Foundation.
This is part of the Life Science Fair Flemingsberg – Precision Health, which runs from 09:00 to 16:00.